Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter.
Posts Tagged ‘NASDAQ:PTGX’
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
Top 10 Trending Stocks as AI Hype Fades
The US stock market took a major hit recently due to tariff-related uncertainties and a broader concern about AI stock valuations.
10 Best Healthcare Stocks For Long-Term Investment
In the US, healthcare expenditures and costs have been increasing.
10 Cheap Biotech Stocks to Invest in Now
Biotechnology stocks are among the most volatile in the market due to their high risk.
8 High Growth High Margin Stocks to Invest In Now
When investor confidence is high, capital tends to flow into growth sectors, driving up stock prices and valuations.
10 Best Healthcare Stocks to Buy Under $50
This article looks at the 10 best healthcare stocks to buy under $50.
Top 5 Stock Picks of Farallon Capital
In this article, we discuss the top 5 stock picks of Farallon Capital.
5 Oversold Biotech Stocks to Buy
In this article, we will take a look at the 5 oversold biotech stocks to buy.
5 Stocks Under $30 to Buy Today According to Billionaire Steven Cohen
In this piece, we will look at the ten stocks under $30 to buy today according to billionaire Steven Cohen.
These 5 Stocks Are Crashing Today
In this article, we take a look at five stocks that are crashing today.
Protagonist Therapeutics, Inc. (PTGX) Fell Out Of Favor With Hedge Funds
In this article we will check out the progression of hedge fund sentiment towards Protagonist Therapeutics, Inc.
5 Small-Cap Stocks to Buy According to Billionaire Steve Cohen
In this article, we discuss the 5 small-cap stocks to buy according to billionaire Steve Cohen.
5 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
In this article, we discuss the 5 best biotech stocks to buy according to Mark Lampert.
5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
Below is the list of 5 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund.
Hedge Funds Are Crazy About Protagonist Therapeutics, Inc. (PTGX)
At Insider Monkey, we pore over the filings of nearly 873 top investment firms every quarter, a process we have now completed for the latest reporting period.
Protagonist Therapeutics, Inc. (PTGX) Fell Out Of Favor With Hedge Funds
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Is PTGX Stock A Buy or Sell?
In this article you are going to find out whether hedge funds think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a good investment right now.
Is PTGX A Good Stock To Buy Now?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Protagonist Therapeutics, Inc. (PTGX): Are Hedge Funds Right About This Stock?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Here is What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Here’s What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX)
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity...
Market Movers Today: Biohaven Pharmaceutical Holding Co Ltd (BHVN), Facebook, Inc. (FB), Longfin Corp (LFIN), Verona Pharma PLC – ADR (VRNA), and More
Biohaven Pharmaceutical Holding Co. Ltd.
13G Filing: Adage Capital Management and Protagonist Therapeutics Inc (PTGX)
You can access the original SEC filing by clicking here.
Wondering What’s Happening in the Financial Markets Today? Check Out These 31 Stories!
"U.S. stocks edged lower on Tuesday as weakness in the energy and financial sectors outweighed gains in technology shares.
Protagonist Therapeutics Inc (PTGX): RA Capital Management Acquires 6.8% Stake
Peter Kolchinsky's RA Capital Management reported via a recent 13G filing with the SEC that it has taken a new position in a company that has recently gone public, Protagonist...
Protagonist Therapeutics Inc (PTGX): Adage Capital Management Reveals 9.69% Stake
Phil Gross (pictured below) and Robert Atchinson's Adage Capital Management recently made a new addition to its portfolio, initiating a position in Protagonist Therapeutics ...
